tiprankstipranks
Advertisement
Advertisement

ANAB Stock Latest News

Is ANAB a Buy, Before Earnings?
Pre-EarningsIs ANAB a Buy, Before Earnings?
2d ago
ANAB
AnaptysBio Enters Key Post-Trial Phase in Tesaro Dispute
PremiumCompany Announcements
AnaptysBio Enters Key Post-Trial Phase in Tesaro Dispute
10d ago
8K
ANAB
Buy Rating Reaffirmed on Litigation Clarity and Asset Value; $95 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Litigation Clarity and Asset Value; $95 Price Target Maintained
19d ago
ANAB
AnaptysBio falls -10.8%
PremiumThe Fly
AnaptysBio falls -10.8%
25d ago
ANAB
AnaptysBio: Buy Rating Reiterated as Jemperli Data De-Risks Program; $95 Price Target Maintained
PremiumRatings
AnaptysBio: Buy Rating Reiterated as Jemperli Data De-Risks Program; $95 Price Target Maintained
27d ago
ANAB
AnaptysBio Subleases San Diego Facility to First Tracks
PremiumCompany AnnouncementsAnaptysBio Subleases San Diego Facility to First Tracks
2M ago
8K
ANAB
AnaptysBio assumed with a Buy at H.C. Wainwright
Premium
The Fly
AnaptysBio assumed with a Buy at H.C. Wainwright
2M ago
ANAB
AnaptysBio Details Tax Treatment of Spin-Off Dividend
Premium
Company Announcements
AnaptysBio Details Tax Treatment of Spin-Off Dividend
2M ago
8K
ANAB
AnaptysBio Adjusts Fiscal Year-End and Reporting Calendar
PremiumCompany Announcements
AnaptysBio Adjusts Fiscal Year-End and Reporting Calendar
3M ago
8K
ANAB
AnaptysBio price target raised to $90 from $85 at Leerink
PremiumThe Fly
AnaptysBio price target raised to $90 from $85 at Leerink
3M ago
GSK
ANAB
AnaptysBio Split Raises Execution, Cost and Governance Risks as Royalty Dependence and Valuation Uncertainty Grow
PremiumCompany Announcements
AnaptysBio Split Raises Execution, Cost and Governance Risks as Royalty Dependence and Valuation Uncertainty Grow
3M ago
ANAB
AnaptysBio price target raised to $76 from $60 at UBS
PremiumThe Fly
AnaptysBio price target raised to $76 from $60 at UBS
3M ago
ANAB
AnaptysBio price target raised to $75 from $63 at Barclays
PremiumThe FlyAnaptysBio price target raised to $75 from $63 at Barclays
3M ago
ANAB
AnaptysBio reports Q1 EPS ($1.84), consensus (75c)
Premium
The Fly
AnaptysBio reports Q1 EPS ($1.84), consensus (75c)
3M ago
ANAB
AnaptysBio Appoints New CFO and Board Director
Premium
Company Announcements
AnaptysBio Appoints New CFO and Board Director
3M ago
8K
ANAB
AnaptysBio appoints Christopher Murphy as CFO
PremiumThe Fly
AnaptysBio appoints Christopher Murphy as CFO
3M ago
ANAB
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
PremiumThe Fly
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
3M ago
GSK
ANAB
AnaptysBio price target raised to $85 from $66 at Leerink
PremiumThe Fly
AnaptysBio price target raised to $85 from $66 at Leerink
3M ago
ANAB
GSK’s TESARO provides update on AnaptysBio litigation
PremiumThe Fly
GSK’s TESARO provides update on AnaptysBio litigation
3M ago
GSK
ANAB
Joseph Thome Reiterates Buy on AnaptysBio as Royalty-Focused Model and Jemperli Legal Win Support $75 Price Target
PremiumRatingsJoseph Thome Reiterates Buy on AnaptysBio as Royalty-Focused Model and Jemperli Legal Win Support $75 Price Target
3M ago
ANAB
Delaware court dismisses Tesaro breach of contract claim against AnaptysBio
Premium
The Fly
Delaware court dismisses Tesaro breach of contract claim against AnaptysBio
4M ago
GSK
ANAB
First Tracks Biotherapeutics initiated with an Outperform at Leerink
Premium
The Fly
First Tracks Biotherapeutics initiated with an Outperform at Leerink
4M ago
ANAB
TRAX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >